科研级 Faricimab, Anti-ANGPT2 & VEGFA Recombinant Antibody, Research Grade Faricimab
Molecular Name
Faricimab
Size
1mg, 5mg
CAS Number
1607793-29-2
Isotype
IgG1 Kappa Lambda
Clonality
Monoclonal
Concentration
1mg/ml
Source
CHO Cells
Purity
≥95% as determined by SDS-PAGE
Buffer
Supplied in PBS, PH7.5
Target
ANGPT2/VEGFA[Homo sapiens]
Background
Faricimab (INN) is a bispecific monoclonal antibody that is being investigated for diabetic macular edema. This drug is being developed by Hoffmann-La Roche. As of 2018, faricimab is undergoing Phase III trials.